Ayala Pharmaceuticals, Inc.
ADXS · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $4 | $4 | $5 | $6 |
| - Cash | $5 | $2 | $7 | $17 |
| + Debt | $8 | $3 | $2 | $2 |
| Enterprise Value | $7 | $6 | -$1 | -$10 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 125% | – |
| Gross Profit | $0 | -$7 | $0 | $0 |
| % Margin | – | – | 0% | 0% |
| EBITDA | -$9 | -$7 | -$8 | -$12 |
| % Margin | – | – | -94,288.9% | -295,625% |
| Net Income | -$25 | -$7 | -$9 | -$7 |
| % Margin | – | – | -96,655.6% | -184,025% |
| EPS Diluted | -4.1 | -1.53 | -1.82 | -1.67 |
| % Growth | -168% | 15.9% | -9% | – |
| Operating Cash Flow | -$7 | -$7 | $0 | -$7 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7 | -$7 | $0 | -$7 |